YZYBIO-B

Wuhan Youzhiyou Biopharmaceutical Co., Ltd. is a biotechnology company dedicated to developing bispecific antibody (BsAb) -based therapies for the treatment of cancer-related complications, cancer, and senile ophthalmology to address medical needs in the fields of oncology and geriatric ophthalmology. The company's mission is to develop innovative medicines and protect human health. Since its establishment in 2010, Tomochiyo Biotech has continued to innovate independently, lay out and deepen the field of bispecific antibodies, and has developed 4 innovative platforms, including the self-developed YBODY platform, the Check-body platform, the Nano-YbodyTM platform, and the UVAX platform developed in cooperation with the Wuhan Institute of Virology. The company has designed and developed seven clinical-stage drug candidate pipelines.